Injectable Hydrogel Depot Sustains GALNS Enzyme Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapy for Mucopolysaccharidosis type IV A, which involves GALNS enzyme, requires weekly infusions due to the enzyme's short half-life of 2.9 minutes, necessitating a more effective delivery method for sustained enzyme release.
Innovation Solution
Development of an injectable GALNS hydrogel formulation comprising GALNS, a polymer, and a buffer solution, encapsulated in a PEG hydrogel depot for sustained release and delivery using a syringe applicator, allowing for extended enzyme activity up to 7 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GALNS enzyme is delivered via weekly infusions, then enzyme replacement therapy is effective, but the treatment frequency is high and patient burden is significant due to the enzyme's short half-life
Solution Approach 1:
The patent changes the physical state and release parameters of the enzyme by encapsulating GALNS in a hydrogel matrix. This transforms the delivery system from direct infusion (immediate release) to hydrogel-encapsulated delivery (sustained release), extending the enzyme's effective presence in the body from minutes to days, thereby reducing treatment frequency while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates a composite material system consisting of the GALNS enzyme encapsulated within a hydrogel matrix. This composite structure allows the enzyme to be delivered in a controlled manner, combining the biological activity of the enzyme with the sustained release properties of the hydrogel, thus reducing the need for frequent administrations
2Duration of action of moving object
If GALNS enzyme half-life is extended, then treatment frequency can be reduced, but the natural half-life of the enzyme is only 2.9 minutes and cannot be inherently changed
Solution Approach 1:
The patent introduces a hydrogel matrix as an intermediary carrier between the enzyme and the biological environment. This hydrogel intermediary protects the enzyme from rapid degradation and clearance, extending its effective half-life from 2.9 minutes to several days, while the enzyme itself retains its natural biochemical properties and catalytic function
3Ease of operation
If enzyme is delivered in solution form, then delivery is simple, but enzyme activity is lost rapidly due to short circulation half-life
Solution Approach 1:
The patent changes the physical formulation parameter from a simple aqueous solution to a hydrogel-based injectable formulation. This formulation change allows the enzyme to be administered via injection (maintaining ease of operation) while the hydrogel matrix provides sustained release, extending enzyme activity duration from minutes to days without requiring complex delivery infrastructure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel formulation provides a sustained release of GALNS enzyme, reducing the frequency of injections from weekly to potentially once every 7 days, maintaining enzyme activity and efficacy while minimizing the need for frequent infusions.
Implementation Method 1
sustained release of enzymes from injectable hydrogel depots
Implementation Method 2
encapsulated in a PEG hydrogel depot for sustained release
Data Source
AI summary
Compositions and methods for delivering enzymes in enzyme hydrogel formulations are disclosed. More particularly, the present disclosure relates to injectable enzyme hydrogel formulations and delivery of injectable enzyme hydrogel formulations. Also disclosed are methods for GALNS enzyme replacement therapy and lysosomal enzyme replacement therapy.